Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study
暂无分享,去创建一个
G Hu | J Tuomilehto | K Borch-Johnsen | J. Tuomilehto | B. Balkau | K. Pyörälä | K. Borch-Johnsen | G. Hu | Q. Qiao | K Pyörälä | Q Qiao | B Balkau | K. Pyörälä | Gang Hu | Kalevi Pyörälä | Qing Qiao | K. Borch-Johnsen | Jaakko Tuomilehto | The Decode Study Group | on behalf of the European Diabetes Epidemiology Group
[1] R. Jung,et al. Controlled trial of effect of documented cardiovascular risk scores on prescribing , 2003, BMJ : British Medical Journal.
[2] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.
[3] H. Tunstall-Pedoe. Coronary heart disease. , 1991, BMJ.
[4] S M Grundy,et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. , 1998, Circulation.
[5] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[6] J. Buring,et al. Development of Predictive Models for Long-Term Cardiovascular Risk Associated With Systolic and Diastolic Blood Pressure , 2002, Hypertension.
[7] B. Balkau,et al. Is there a glycemic threshold for mortality risk? , 1999, Diabetes care.
[8] F. Cappuccio,et al. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study , 2002, BMJ : British Medical Journal.
[9] K. Eriksson,et al. Influence of Plasma Fibrinogen Levels on the Incidence of Myocardial Infarction and Death Is Modified by Other Inflammation-Sensitive Proteins: A Long-Term Cohort Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[10] R. Holman,et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.
[11] A. Menotti,et al. Prediction of coronary heart disease in Europe. The 2nd report of the WHO-ERICA Project. ERICA Research Group. , 1991, European heart journal.
[12] M W Knuiman,et al. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. , 1997, Journal of epidemiology and community health.
[13] A. Folsom,et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. , 2003, Journal of clinical epidemiology.
[14] W. Kannel,et al. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. , 1982, American heart journal.
[15] Ose,et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .
[16] Helmut Schulte,et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. , 2003, European heart journal.
[17] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[18] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[19] Beverley Balkau,et al. High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.
[20] J. Tuomilehto,et al. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? , 2003, Diabetes care.
[21] W. Kannel,et al. The coronary profile: 12-year follow-up in the Framingham study. , 1967, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[22] T. Jørgensen,et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. , 2002, International journal of epidemiology.
[23] F. Game,et al. Coronary heart disease risk assessment in diabetes mellitus–‐a comparison of PROCAM and Framingham risk assessment functions , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[24] R B D'Agostino,et al. Cardiovascular Risk Assessment Based on US Cohort Studies: Findings From a National Heart, Lung, and Blood Institute Workshop , 2001, Circulation.
[25] G. Assmann,et al. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.
[26] L. Bouter,et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.
[27] J. Kirkpatrick. Albuminuria and Risk of Cardiovascular Events , Death , and Heart Failure in Diabetic and Nondiabetic Individuals , 2002 .
[28] Nancy R Cook,et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.
[29] I. U. Haq,et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.
[30] S. Yusuf,et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.
[31] H Tunstall-Pedoe,et al. The Dundee coronary risk-disk for management of change in risk factors. , 1991, BMJ.
[32] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .
[33] R. Stevens,et al. UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine , 2002, Stroke.
[34] G. Chatellier,et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients , 2002, Journal of hypertension.
[35] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[36] R. Jackson. Guidelines on preventing cardiovascular disease in clinical practice , 2000, BMJ : British Medical Journal.
[37] E. Feskens,et al. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.
[38] E. Feskens,et al. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.
[39] François Gueyffier,et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials , 2001, BMJ : British Medical Journal.
[40] P Ducimetière,et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. , 2003, European heart journal.
[41] G. Hu,et al. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes , 2003, Diabetologia.